Cannabics Pharmaceuticals Inc . announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases.
|
TEL AVIV, Israel and BETHESDA, Maryland, Sept. 21, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals. (CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today the hire of Dr. David Sans FAARM, PhD, MBA in New York to expand its current pipeline of clinical development assets in Mental Health Diseases. This announcement comes following the company’s commitment to expand the current drug development programs with second generation of synthetic psychedelic inspired drugs.
Gabriel Yariv, company Executive Chairman said: “Psychedelic compounds have an increasing favorable regulatory environment and a growing body of clinical trials data demonstrating a remarkable degree of efficacy in difficult to treat mental health conditions. It is for these reasons that we are interested in this area, for helping patients with difficulties in treating their Mental Health Diseases and having a positive impact by expanding our current pipeline of synthetic compounds and investing in well-positioned, second-generation, synthetic psychedelic inspired medicine.” Eyal Barad, Cannabics Pharmaceuticals’ Co-founder and CEO commented: “Dr. David Sans is a Healthcare Investment Banker in New York with over 12 years of banking experience and a wealth of knowledge in the CNS industry. David has led a number of transactions that are very relevant to Cannabics Pharmaceuticals and we welcome the opportunity to working with him.” About Cannabics Pharmaceuticals: Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company and a global leader in the development of cancer related cannabinoid-based medicine. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn, and on Instagram @Cannabics_Pharmaceuticals. Read more: Recent expansion of Cannabics Pharmaceuticals’ Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.). Recent expansion of Cannabics Pharmaceuticals’ Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors. Disclaimer: Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our Company’s management and are subject to significant risks and uncertainties. Actual results may differ from those outlined in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-Q Report filed July 14th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc., which are condoned by the Company, must emanate from the Company itself and bear our name as its source. For more information about Cannabics: Related Links
SOURCE Cannabics Pharmaceuticals Inc. | ||
Company Codes: OTC-PINK:CNBX, Munich:8C8, Stuttgart:8C8 |
View original content:
